Drug Discovery for Psychiatric Disorders
The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders.
Drug Discovery for Psychiatric Disorders, The Royal Society of Chemistry, 2012.
Download citation file:
Digital access
Print format
Table of contents
-
Psychiatric Disorders – an Overviewp1-9ByDavid MichelsonDavid MichelsonSearch for other works by this author on:
-
CHAPTER 2: The Pathophysiology of Schizophreniap13-34ByArmin Szegedi;Armin SzegediMerck & Co., Inc., Department of Clinical NeuroscienceMRL, Building 34 Room A5045, 1E Lincoln Ave, Rahway, NJ 07065USASearch for other works by this author on:Michael EganMichael EganMerck & Co., Inc., Department of Clinical NeuroscienceMRL, 351 Sumneytown Pike, UG4C-06, North Wales, PA 19454USA[email protected]Search for other works by this author on:
-
CHAPTER 3: Monoaminergic Approaches for Treatment of Schizophreniap35-55ByDavid P. RotellaDavid P. RotellaMargaret and Herman Sokol Professor of Medicinal Chemistry, Department of Chemistry and Biochemistry, Sokol Institute for Pharmaceutical Life SciencesMontclair State University, Montclair, NJ07043, USA[email protected]Search for other works by this author on:
-
CHAPTER 4: Glutamatergic Approaches for the Treatment of Schizophreniap56-98ByJohn A. Morrow;John A. MorrowNeuroscience and Ophthalmology, Merck Research Laboratories2015 Galloping Hill Road, Kenilworth, New Jersey 07033USA[email protected]Search for other works by this author on:Robert Gilfillan;Robert GilfillanDiscovery Chemistry, Merck Research Laboratories770 Sumneytown Pike, West Point, Pennsylvania 19486USASearch for other works by this author on:Stuart A. NealeStuart A. NealeNeurexpert LtdGround Floor, 2 Woodberry Grove, North Finchley, London, N12 0DRUKSearch for other works by this author on:
-
CHAPTER 5: Discovery and Clinical Data for a Novel AMPA Receptor Positive Modulatorp99-122BySimon E. WardSimon E. WardProfessor of Medicinal Chemistry & Director of Translational Drug Discovery Group, School of Life SciencesUniversity of SussexBrighton, BN1 9QJUnited Kingdom[email protected]Search for other works by this author on:
-
CHAPTER 6: Treating the Cognitive Deficits of Schizophreniap123-156ByBruce N. Rogers;Bruce N. RogersWorldwide Medicinal Chemistry – NeurosciencePfizer Global Research and Development700 Main Street, Cambridge, MA 02139USA[email protected]Search for other works by this author on:David L. GrayDavid L. GrayWorldwide Medicinal Chemistry – NeurosciencePfizer Global Research and Development700 Main Street, Cambridge, MA 02139USA[email protected]Search for other works by this author on:
-
CHAPTER 7: The Neurobiology of Depression and Anxiety: How Do We Change from Models of Drug Efficacy to Understanding Mood and Anxiety Disorders?p159-183ByGeorgia E. Hodes;Georgia E. HodesFishberg Department of Neuroscience and Freidman Brain InstituteMount Sinai School of Medicine1425 Madison Ave., New York, NY 10029USA[email protected]Search for other works by this author on:Scott J. RussoScott J. RussoFishberg Department of Neuroscience and Freidman Brain InstituteMount Sinai School of Medicine1425 Madison Ave., New York, NY 10029USA[email protected]Search for other works by this author on:
-
CHAPTER 8: Beyond SSRIs: Second-generation Reuptake Inhibitors for the Treatment of Depressionp184-225ByPeter T. GallagherPeter T. GallagherSearch for other works by this author on:
-
CHAPTER 9: Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorderp226-257ByJames W. Murrough;James W. MurroughMood and Anxiety Disorders Program, Mount Sinai School of Medicine1 Gustave L. Levy Place, Box 1230, New York, NY 10029USADepartment of Psychiatry, Mount Sinai School of MedicineDepartment of Neuroscience, Mount Sinai School of MedicineFriedman Brain Institute, Mount Sinai School of Medicine.[email protected]Search for other works by this author on:Daniela Schiller;Daniela SchillerLaboratory of Affective Neuroscience, Mount Sinai School of MedicineDepartment of Psychiatry, Mount Sinai School of MedicineDepartment of Neuroscience, Mount Sinai School of MedicineFriedman Brain Institute, Mount Sinai School of Medicine.[email protected]Search for other works by this author on:Dennis S. Charney, MDDennis S. Charney, MDDepartment of Psychiatry, Mount Sinai School of MedicineDepartment of Neuroscience, Mount Sinai School of MedicineDepartment of Pharmacology, Mount Sinai School of MedicineOffice of the Dean, Mount Sinai School of MedicineFriedman Brain Institute, Mount Sinai School of Medicine.[email protected]Search for other works by this author on:
-
CHAPTER 10: Glutamate Approaches Towards the Treatment of Mood Disordersp258-275ByCarrie K. Jones;Carrie K. JonesVanderbilt University Medical School, Department of PharmacologyVanderbilt Center for Neuroscience Drug Discovery1205 LH, Nashville, TN 37232-0697USA[email protected]Search for other works by this author on:P. Jeffrey Conn;P. Jeffrey ConnVanderbilt University Medical School, Department of PharmacologyVanderbilt Center for Neuroscience Drug Discovery1205 LH, Nashville, TN 37232-0697USA[email protected]Search for other works by this author on:Craig W. LindsleyCraig W. LindsleyVanderbilt University Medical School, Department of PharmacologyVanderbilt Center for Neuroscience Drug Discovery1205 LH, Nashville, TN 37232-0697USA[email protected]Search for other works by this author on:
-
CHAPTER 11: Modulation of HPA Axis Function for Treatment of Mood Disordersp276-299ByShaun P. Brothers;Shaun P. BrothersDepartment of Psychiatry and Behavioral SciencesUniversity of Miami Miller School of Medicine, 1120 Northwest 14 Street, Suite 1455 Miami, Florida 33136[email protected]Search for other works by this author on:Claes Wahlestedt;Claes WahlestedtDepartment of Psychiatry and Behavioral SciencesUniversity of Miami Miller School of Medicine, 1120 Northwest 14 Street, Suite 1455 Miami, Florida 33136[email protected]Search for other works by this author on:Charles B. NemeroffCharles B. NemeroffDepartment of Psychiatry and Behavioral SciencesUniversity of Miami Miller School of Medicine, 1120 Northwest 14 Street, Suite 1455 Miami, Florida 33136[email protected]Search for other works by this author on:
-
CHAPTER 12: Neuropeptide Receptors: Novel Therapeutic Targets for Depression and Anxiety Disordersp300-330ByShigeyuki Chaki;Shigeyuki ChakiMolecular Function and Pharmacology Laboratories andSearch for other works by this author on:Kosuke KanumaKosuke KanumaMedicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd1-403 Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530Japan[email protected]Search for other works by this author on:
-
CHAPTER 13: Therapeutic Approaches to Bipolar Disorderp333-356ByMoghis U. Ahmad;Moghis U. AhmadJina Pharmaceuticals Inc.28100 N. Ashley Circle, Suite 103, LibertyvilleIllinois 60048USA[email protected]Search for other works by this author on:Shoukath M. Ali;Shoukath M. AliJina Pharmaceuticals Inc.28100 N. Ashley Circle, Suite 103, LibertyvilleIllinois 60048USA[email protected]Search for other works by this author on:Saifuddin Sheikh;Saifuddin SheikhJina Pharmaceuticals Inc.28100 N. Ashley Circle, Suite 103, LibertyvilleIllinois 60048USA[email protected]Search for other works by this author on:Ateeq Ahmad;Ateeq AhmadJina Pharmaceuticals Inc.28100 N. Ashley Circle, Suite 103, LibertyvilleIllinois 60048USA[email protected]Search for other works by this author on:Imran AhmadImran AhmadJina Pharmaceuticals Inc.28100 N. Ashley Circle, Suite 103, LibertyvilleIllinois 60048USA[email protected]Search for other works by this author on:
-
CHAPTER 14: Pharmacotherapies for Drug Addictionp357-383ByC. D. Gipson;C. D. GipsonDepartment of NeurosciencesMedical University of South Carolina173 Ashley Avenue, 205 DDB, Charleston, SC 29425USA[email protected]Search for other works by this author on:P. W. KalivasP. W. KalivasDepartment of NeurosciencesMedical University of South Carolina173 Ashley Avenue, 205 DDB, Charleston, SC 29425USA[email protected]Search for other works by this author on:
-
CHAPTER 15: Emerging Research towards the Understanding and Treatment of Autismp384-415ByAileen HealyAileen HealySearch for other works by this author on:
-
CHAPTER 16: Recent Chronology of Orexin Pharmacology and Its Potential as a Treatment for Primary Insomniap416-442ByChristopher J. Winrow;Christopher J. WinrowMerck Research Laboratories, Neuroscience Department770 Sumneytown Pike, West Point, PA 19486USA[email protected]Search for other works by this author on:Anthony L. Gotter;Anthony L. GotterMerck Research Laboratories, Neuroscience Department770 Sumneytown Pike, West Point, PA 19486USA[email protected]Search for other works by this author on:Paul J. Coleman;Paul J. ColemanMerck Research Laboratories, Medicinal Chemistry Department770 Sumneytown Pike, West Point, PA 19486USASearch for other works by this author on:Richard Hargreaves;Richard HargreavesMerck Research Laboratories, Neuroscience Department770 Sumneytown Pike, West Point, PA 19486USA[email protected]Search for other works by this author on:John J. RengerJohn J. RengerMerck Research Laboratories, Neuroscience Department770 Sumneytown Pike, West Point, PA 19486USA[email protected]Search for other works by this author on:
-
CHAPTER 17: Crossing the Blood-brain Barrier – Methods for Evaluating CNS Exposurep445-464ByJames A. Baker;James A. BakerPharmacokinetics, Pharmacodynamics and Drug MetabolismMerck Research Laboratories33 Avenue Louis Pasteur, Boston, MA 02115USA[email protected]Search for other works by this author on:Iain J. MartinIain J. MartinPharmacokinetics, Pharmacodynamics and Drug MetabolismMerck Research Laboratories33 Avenue Louis Pasteur, Boston, MA 02115USA[email protected]Search for other works by this author on:
-
CHAPTER 18: Medicinal Chemistry Challenges in CNS Drug Discoveryp465-509ByZoran RankovicZoran RankovicSearch for other works by this author on:
-
CHAPTER 19: Multi-target Drug Discovery for Psychiatric Disordersp510-533ByRichard MorphyRichard MorphyEli Lilly and CompanyErl Wood ManorWindlesham, Surrey, GU20 6PHUKSearch for other works by this author on:
-
CHAPTER 20: The Possibilities and Limitations of Animal Models for Psychiatric Disordersp534-557ByMark D. Tricklebank;Mark D. TricklebankLilly Centre for Cognitive NeuroscienceEli Lilly and Co. Ltd, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PHUK[email protected]Search for other works by this author on:Joseph P. GarnerJoseph P. GarnerDepartment of Comparative Medicine and, by courtesy, Department of Psychiatry and Behavioral SciencesStanford University287 Campus Drive, Stanford, CA 94305-5410USASearch for other works by this author on:
-
CHAPTER 21: Translational PET Imaging Research in Psychiatryp558-573ByEugenii A. RabinerEugenii A. RabinerImanova LimitedBurlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NNUKSearch for other works by this author on:
-
CHAPTER 22: Future Drug Discovery for Psychiatric Disordersp574-578ByDarryle D. Schoepp;Darryle D. SchoeppMerck Research LaboratoriesMerck and Company, Inc.1351 Sumneytown Pike, UG/4CDS013, North Wales, PA 19454USA[email protected]Search for other works by this author on:Richard J. HargreavesRichard J. HargreavesMerck Research LaboratoriesMerck and Company, Inc.1351 Sumneytown Pike, UG/4CDS013, North Wales, PA 19454USA[email protected]Search for other works by this author on:
Spotlight
Advertisement
Advertisement